Full Text Available
Note: Clicking the button above will open the full text document at the original institutional repository in a new window.
Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
Saved in:
| Published in: | EJNMMI Research |
|---|---|
| Format: | Online Article RSS Article |
| Published: |
2026
|
| Subjects: | |
| Tags: |
No Tags, Be the first to tag this record!
|
Similar Items: Outcome and safety of single-dose docetaxel–augmented targeted radionuclide therapy using [¹⁷⁷Lu]Lu-PSMA-617 radioligand therapy in treatment-refractory mCRPC: preliminary evidence from a pilot experience
- Fractionation gives therapeutic benefit in animal model of [Lu]Lu-PSMA-617 therapy of prostate cancer
- Dosimetry of [Lu]Lu-PSMA therapy in a hemodialysis patient: a case study
- Most ReLU Networks Admit Identifiable Parameters
- Exact ReLU realization of tensor-product refinement iterates
- Random ReLU Neural Networks as Non-Gaussian Processes
- Random ReLU Neural Networks as Non-Gaussian Processes